

World Cord Blood Congress V
&
Innovative Cell Therapies
Monaco
5-8 March 2015

Chairperson: E. Gluckman (Paris)

Scientific Committee: E. Baudoux (Liège), H.E. Broxmeyer (Indianapolis), M. Cavazzana (Paris), J. Elion (Paris),
T. Enver (London), G. Koegler (Dusseldorf), J. Kurtzberg (Durham), E. Petersdorf (Seattle),
V. Rocha (Oxford), E.J. Shpall (Houston), J. Wagner (Minneapolis)

Under the High Patronage of his Serene Highness Prince Albert II of Monaco

Programme

Thursday, March 5th, 2015

Opening 13.45-14.00

14.00-16.30 SESSION I - STEM CELL BIOLOGY

Chair: T. Enver (London)

14.00-14.30	State of the art	T. Enver (London)
14.30-14.50	EPHOSS and DPP4: new mechanisms and manipulation for clinical advantage for cord blood transplantation	H.E. Broxmeyer (Indianapolis)
14.50-15:10	Do we need a different niche for fast haematopoietic reconstitution in cord blood transplantation?	G. Koegler (Düsseldorf)
15.10-15.30	Early stem cell fate decisions towards establishment of lympho-myeloid components of the immune-system	S.E. Jacobsen (Oxford)
15.30-15.50	Programming haematopoietic stem cells during development	R. Patient (Oxford)
15.50-16.10	UM171 expansion of human CB stem cells	G. Sauvageau (Montreal)

16.10-16.30 *Discussion*

16.30-17.00 *Coffee break*

17.00-19.00 SESSION II - METHODS OF GRAFT FACILITATION I

Chair: E.J. Shpall (Houston)

17.00-17.30	State of the art	E.J. Shpall (Houston)
17.30-17.50	Stem Regimen-1 Expanded umbilical cord blood transplantation	J. Wagner (Minneapolis)
17.50-18.10	Nicord expands haematopoietic stem cells and shortens time to engraftment in patients undergoing cord blood transplantation for haematological malignancies and sickle cell disease	J. Kurtzberg (Durham)
18.10-18.30	Notch ligand-based expansion strategies: development of an ex vivo expanded universal donor progenitor cell therapy	C. Delaney (Seattle)

18.30-19.00 *Discussion*

19.00-19.30 *Opening ceremony*

19.30 *Reception: Congress Centre*

08.30-10.30	SESSION III - METHODS OF GRAFT FACILITATION II Chair: HE. Broxmeyer (Indianapolis)	
08.30-09.00	State of the art	H.E. Broxmeyer (Indianapolis)
09.00-09.20	Can MSC facilitate engraftment and haematopoietic reconstitution?	F. Dazzi (London)
09.20- 09.40	Single versus double cord blood transplant in children	J. Wagner (Minneapolis)
09.40-10.00	Single versus double cord blood transplant in adults	A. Ruggeri (Paris)
10.00-10.30	<i>Discussion</i>	
10.30-11.00	<i>Coffee break</i>	
11.00-13.00	SESSION IV - <i>in association with</i> NETCORD & WMDA: EVOLUTION IN CORD BLOOD BANKING Chair: E. Baudoux (Liège)	
11.00-11.20	Improving quality of cord blood banks	E. Baudoux (Liège)
11.20-11.40	Cost efficiency of cord blood banks	S. Querol (Barcelona)
11.40-12.00	Haplotype diversity in cord blood units	M. Boo (Minneapolis)
12.00-12.20	Contribution of Eurocord registry to the improvement of cord blood banking	I. Ionescu (Saint Denis)
12.20-12.45	<i>Discussion</i>	
12.45-14.30	<i>Lunch and poster viewing</i>	
13.15-14.30	<u>SATELLITE WORKSHOP #1</u>	
14.30-16.30	SESSION V - IMMUNOGENETICS OF DONOR CHOICE Chair: E. Petersdorf (Seattle)	
14.30-14.50	State of the art	E. Petersdorf (Seattle)
14.50-15.10	Selecting cord blood units in 2015	M. Eapen (Milwaukee)
15.10-15.25	The role of NK cell killer immunoglobulin receptor genomics on the outcome of cord blood transplantation	K. Rezvani (Houston)
15.25-15.45	The complexity of the MHC in HLA matching with the use of next generation sequencing technologies	A. Madrigal (London)
15.45-16.00	Analysis of classical HLA haplotypes can predict outcomes of haematopoietic stem cell transplantation	R. Tamouza (Paris)
16.00-16.30	<i>Discussion</i>	
16.30-17.00	<i>Coffee break</i>	
17.00-18.30	SESSION VI - ETHICAL AND LEGAL ASPECTS Chair: W. Arcese (Rome)	
17.00-17.20	So called "MSCs": concepts and misconceptions, use and misuse, science and empirism	P. Bianco (Rome)

17.20-17.40	Cell-based therapies in Europe: legal requirements and ethical issues	A. Altavilla (Marseille)
17.40-18.30	Round table discussion E. Gluckman (Paris), W. Arcese (Rome), E. Baudoux (Liège), S. Querol (Barcelona), J. Kurtzberg (Durham), J. Wagner (Minneapolis), P. Bianco (Rome), A. Altavilla (Marseille) F. Mourou (Monaco – Association Cordons de Vie)	

Saturday, March 7th, 2015

08.30-10.00	SESSION VII - CURRENT RESULTS OF CORD BLOOD TRANSPLANTATION RESULTS IN CHILDREN: Chair: F. Locatelli (Rome)	
08.30-08.50	Transplantation of cord blood cells as a successful treatment in children with haemoglobinopathies	F. Locatelli (Rome)
08.50-09.10	Importance of CD4+ lymphocyte reconstitution following cord blood transplantation	P. Veys (London)
09.10-09.30	Towards individualized conditioning regimens to improve the outcomes of cord blood transplantation	J. Boelens (Utrecht)
09.30-09.50	UCBT for childhood AML : the impact of cytogenetic	G. Michel (Marseille)
	RESULTS IN ADULTS: Chair: V. Rocha (Oxford)	
09.50-10.10	Are the criteria of donor choice in adults different from children ?	V. Rocha (Oxford)
10.10-10.30	How to improve cord blood transplant results in adults	J. Sanz (Valencia)
10.30-11.00	<i>Coffee break</i>	
11.00-12.30	SESSION VIII - IMMUNOMODULATION FOR CORD BLOOD TRANSPLANTATION Chair: J. Wagner (Minneapolis)	
11.00-11.30	Redirecting T cell specificity post transplant	C. June (Philadelphia)
11.30-11.50	Prevention of GVHD by umbilical cord blood derived T- regulatory cells	J. Wagner (Minneapolis)
11.50-12.10	Therapeutic immune regulation with mesenchymal stromal cells	W. Fibbe (Leiden)
12.10-12.30	<i>Discussion</i>	
12.30-14.30	<i>Lunch and poster viewing</i>	
13.00-14.15	<u>SATELLITE WORKSHOP #2</u>	
14.30-16.30	SESSION IX - COMPARISON WITH OTHER SOURCES OF STEM CELLS Chair: M. Eapen (Milwaukee)	
14.30-15.00	T cell-replete, HLA-haploidentical stem cell transplantation	E. Fuchs (Baltimore)
15.00-15.20	Comparison of cord blood and non T depleted related haplo transplant in adults	A. Ruggeri (Paris)
15.20-15.40	Comparison of cord blood transplant to T depleted haplo transplant in children	F. Locatelli (Rome)
15.40-16.00	Prospective study on allogeneic transplant in acute myeloid leukaemia according to the policy of the Rome Transplant network for donor selection: HLA identical sibling vs matched unrelated vs haploidentical related donor	W. Arcese (Rome)

16.00-16.20	Is survival better when patients are enrolled on a clinical trial?	M. Eapen (Milwaukee)
16.20-17.00	Discussion	
17.00- 17.30	Coffee break	
17.30-19.00	SESSION X - SELECTED ABSTRACTS FOR ORAL PRESENTATION Chair: J. Kurtzberg (Durham)	

Sunday, March 8th, 2015

08.30-10.00	SESSION XI - in association with Monacord and Centre Scientifique de Monaco : DEVELOPMENT OF STEM CELL TRANSPLANT IN EMERGING COUNTRIES: THE EXAMPLE OF SICKLE CELL ANAEMIA Chair: E. Gluckman (Paris)	
08.30-08.45	Establishing a transplant program in emerging countries	D. Diallo (Bamako)
08.45-09.00	Access to safe and effective transfusion clinical program	S. Diop (Dakar)
09.00-09.15	Treatment of sickle cell disease in emerging countries	M. de Montalembert (Paris)
09.15-09.30	Indication of bone marrow transplantation in sickle cell disease	F. Bernaudin (Créteil)
09.30-09.45	Bone marrow transplant for sickle cell disease in Brazil	B. Simoes (Ribeiro Preto)
09.45-10.00	International survey of haematopoietic stem cell transplant for sickle cell disease	B. Cappelli (Monaco)
10.00-10.30	Coffee break	
10.30-13.00	SESSION XII - NEW INNOVATIVE THERAPY TO TREAT NON-MALIGNANT DISEASES Chair: M. Cavazzana (Paris)	
10.30-10.50	Gene therapy for hereditary disorders	M. Cavazzana (Paris)
10.50- 11.10	Engineering intrinsic resistance to HIV infection	C. June (Philadelphia)
11.10-11.30	Update on haematopoietic and mesenchymal cell therapy for the treatment of autoimmune diseases	D. Farge (Paris)
11.30-12.00	Immunopsychiatry: from pathways to innovative therapies	M. Leboyer (Paris) R. Tamouza (Paris)
12.00-12.20	Indications and results of the use of stem cells for regenerative medicine	G. Koegler (Düsseldorf)
12.20-12.40	The potential of cord blood to treat genetic and acquired brain diseases	J. Kurtzberg (Durham)
12.40-13.00	Discussion	

Conclusion